1. Home
  2. XTNT
  3. Earnings

AI Earnings Predictions for Xtant Medical Holdings Inc. (XTNT)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-4.86%

$0.21

0% positive prob.

5-Day Prediction

-9.51%

$0.20

0% positive prob.

20-Day Prediction

-6.83%

$0.20

0% positive prob.

Price at prediction: $0.22 Confidence: 99.1% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -4.86% -9.51% -6.83% 99.1% Pending
Q2 2026 SELL -4.86% -9.51% -6.83% 99.1% +3.59%
Q1 2026 SELL -5.20% -10.27% -6.48% 99.9% -3.10%
Q3 2025 SELL -5.93% -9.50% -7.60% 100.0% -10.25%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 16, 2026 · 99% conf.

AI Prediction SELL

1D

-4.86%

$0.21

Act: -7.27%

5D

-9.51%

$0.20

20D

-6.83%

$0.20

Price: $0.22 Prob +5D: 0% AUC: 1.000
0001493152-26-051996

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Xtant Medical Reports Third Quarter 2026 Financial Results

and Announces Board-led Strategic Review Process

Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives.

BELGRADE,

Mont., November 16, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

●Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue.

●Biologics revenue was $19.3 million for the third quarter of 2026, up 13% from the third quarter of 2025 and up 11% from the second quarter of 2026, third quarter 2026 revenue includes $2.2 million from sales of HEMOBLAST® Bellows.

“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,” said Stavros Vizirgianakis, Chairman of the Board. “Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board’s interests are directly aligned with stockholders. The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year.”

The Board’s active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required.

Third Quarter 2026 Financial Results

Revenue for the third quarter of 2026 was $24.3 million compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of $5.4 million of prior-year revenue from the divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Biologics revenue was $19.3 million, an increase of 13% from $17.1 million for the third quarter of 2025 and 11% from $17.4 million for the second quarter of 2026. Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement, a non-GAAP measure, grew 8% compared to the second quarter of 2026 and 6% compared to the third quarter of 2025.

Gross margin for the third quarter of 2026 was 56.3%, compared to 66.1% for the same period in 2025. The decrease primarily reflected a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix.

Operating expenses for the third quarter of 2026 were $16.7 million, compared to $19.5 million for the third quarter of 2025. General and administrative expenses decreased to $5.0 million from $7.1 million, due primarily to the divested non-core Coflex/CoFix assets and international hardware business and lower expense under compensation plans. Sales and marketing expenses decreased to $11.2 million from $11.7 million due primarily to savings related to the divestitures and lower consulting fees, partially offset by higher compensation expense from increased sales headcount, including sales personnel hired in connection with the Company’s exclusive U.S. distribution agreement for HEMOBLAST, and by higher independent agent commissions and travel expenses.

Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025.

Adjusted EBITDA, a non-GAAP meas

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 11, 2026 · 99% conf.

AI Prediction SELL

1D

-4.86%

$0.30

Act: -3.00%

5D

-9.51%

$0.29

Act: +3.59%

20D

-6.83%

$0.30

Price: $0.32 Prob +5D: 0% AUC: 1.000
0001493152-26-036979

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Xtant Medical Reports Second Quarter 2026 Financial Results

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures

Company to host investor conference call and webcast today, August 11th, at 8:30am ET

BELGRADE,

Mont., August 11, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

●Generated total revenue of $23.0 million for the second quarter of 2026, as compared to $35.4 million for the second quarter of 2025. The decline in revenue relates primarily to the sale of the non-core Coflex/CoFix assets and international hardware business to Companion Spine in December 2025 as well as license revenue that ceased at the end of 2025 due to changes in the reimbursement environment.

Second Quarter 2026 and Recent Business Highlights

●Announced an exclusive U.S. distribution agreement with privately held Dilon Technologies whereby Xtant has acquired the exclusive U.S. commercial rights to Dilon’s HEMOBLAST® Bellows product for high-performance hemostasis following certain surgical procedures. As part of the transaction, Xtant has hired Dilon’s approximately 20-person U.S. sales team, who will support Xtant’s entire biologics portfolio.

●Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures. Trivium™ Shaped is available in pre-shaped configurations designed to support handling, preparation, and placement across a range of surgical applications.

Sean Browne, President and CEO of Xtant Medical, stated, “The second quarter reflected continued execution of our strategy to broaden our core biologics portfolio while expanding access to more hospitals and surgeons. The Dilon distribution agreement added a complementary hemostatic technology and significant commercial resources, which, together with the introduction of Trivium Shaped, strengthen our platform and position us for sustained long-term growth.”

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $23.0 million, compared to $35.4 million for the same period in 2025. The year-over-year decline is primarily due to the sale of the Company’s non-core Coflex/CoFix assets and international hardware business to Companion Spine in December of 2025, as well as license revenue from Xtant’s Q-code and amniotic membrane agreements in the second quarter of 2025 that did not repeat in the second quarter of 2026 due to changes in the reimbursement environment.

Gross margin for the second quarter of 2026 was 57.9%, compared to 68.6% for the same period in 2025. The decrease was primarily due to the cessation of Q-code high-margin license revenue from the amniotic membrane agreements that ceased at the end of 2025, together with reduced production efficiencies and increased charges for excess and obsolete inventory.

Operating expenses for the second quarter of 2026 totaled $22.5 million, compared to $19.7 million for the second quarter of 2025. The increase was primarily due to a $5.0 million exclusivity fee paid to Dilon Technologies in connection with the Company’s distribution agreement, partially offset by lower general and administrative and sales and marketing expenses following the Company’s December 2025 sale of its Coflex/CoFix assets and international hardware business to Companion Spine.

Second quarter 2026 net loss was $9.4 million, compared to net income of $3.6 million for the second quarter of 2025.

Non-GAAP

adjusted EBITDA loss for the second quarter of 2026 totaled $2.7 million, compared to positive adjusted EBITDA of $6.9 million for the same period in 2025.

The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.

As of June 30, 2026, the Company had $9.9 million of cash and cash equivalents, total indebtedness of $23.0 million, and availability under its revolving credit facility of $0.7 million, compared to $17.3 million of cash and cash equivalents, total indebtedness of $25.4 million, and availability under its revolving credit facility of $3.8 million as of December 31, 2025. The decrease in t

2026
Q1

Q1 2026 Earnings

8-K SELL

May 13, 2026 · 100% conf.

AI Prediction SELL

1D

-5.20%

$0.46

Act: -2.08%

5D

-10.27%

$0.43

Act: -3.10%

20D

-6.48%

$0.45

Act: -10.25%

Price: $0.48 Prob +5D: 0% AUC: 1.000
0001493152-26-022600

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Xtant Medical Reports First Quarter 2026 Financial Results

Raises full-year 2026 revenue guidance to a range of $101-$105 million

Significantly strengthens balance sheet

Enters into exclusive U.S. distribution agreement for Dilon Technologies’ HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon’s U.S. sales team

BELGRADE,

Mont., May 13, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

●Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to Companion Spine in December 2025 as well as 2025 license revenue that will not repeat in 2026.

●Reduced total indebtedness by $13.3 million in the first quarter of 2026, including a $10.4 million reduction in net amounts outstanding under the Company’s revolving line of credit, and a $2.8 million reduction in its term loan balance.

●Increased full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows hemostatic product that was licensed in April 2026.

First Quarter 2026 and Recent Business Highlights

●Announced an exclusive U.S. distribution agreement with privately held Dilon Technologies whereby Xtant has acquired the exclusive U.S. commercial rights to Dilon’s HEMOBLAST® Bellows product for high-performance hemostasis following certain surgical procedures. As part of the transaction, Xtant has hired Dilon’s approximately 20-person U.S. sales team.

●Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures. Trivium™ Shaped is available in pre-shaped configurations designed to support handling, preparation, and placement across a range of surgical applications.

●Received the final $10.7 million due from Companion Spine in March, finalizing the previously announced sale of Xtant’s non-core Coflex®/CoFix assets and its international hardware business to Companion, and resulting in a total cash purchase price of $21.4 million.

Sean Browne, President and CEO of Xtant Medical, stated, “The first quarter of 2026 and subsequent period were pivotal for Xtant. Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST® Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category. We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilon’s 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond. These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio.”

First Quarter 2026 Financial Results

Revenue for the first quarter of 2026 was $20.9 million, compared to $32.9 million for the same period in 2025. The year-over-year decline is primarily due to the sale of the company’s Coflex/CoFix assets and international hardware business to Companion Spine in December of 2025, as well as license revenue from Xtant’s Q-code and amniotic membrane agreements in the first quarter of 2025 that did not repeat in the first quarter of 2026 due to changes in the reimbursement environment.

Gross margin for the first quarter of 2026 was 57.3%, compared to 61.5% for the same period in 2025. The decrease was primarily due to the cessation of Q-code high-margin license revenue from the amniotic membrane agreements that ceased at the end of 2025.

Operating expenses for the first quarter of 2026 totaled $14.9 million, compared to $19.2 million for the first quarter of 2025. The decrease was primarily due to the company’s sale of its Coflex/CoFix assets and international hardware business to Companion Spine in December 2025.

First quarter 2026 net loss was $3.1 million, compared to net income of $58,000 for the first quarter of 2025.

Non-GAAP

adjusted EBITDA loss for the first quarter of 2026 totaled $1.6 million, compared to positive adjusted EBITDA of $3.0 million for the same period in 2025.

The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related income an

About Xtant Medical Holdings Inc. (XTNT) Earnings

This page provides Xtant Medical Holdings Inc. (XTNT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on XTNT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: